The two most widely studied immune checkpoints to date in human cancer are the PD-1 (a.k.a. CD279) and the CTLA-4 (a.k.a. CD152), which were discovered in 1992 and 1995, respectively [208, 209]. This evidence concerns the gene PDCD1 and cancer.